Robert Manguso is an Assistant Professor at the Massachusetts General Hospital Krantz Family Center for Cancer Research and Harvard Medical School, and an Associate Member at the Broad Institute. The major focus of the Manguso lab is to understand how cancers evade the immune system and discover new ways to improve cancer immunotherapy. They use a range of approaches including mouse models, functional genomics, cellular immunology, and single-cell profiling to reveal the mechanistic basis for cancer immune evasion. The Manguso lab has pioneered the use of in vivo genetic screens with CRISPR to identify new immunotherapy targets and resistance mechanisms. These approaches have led to the discovery of important new immune checkpoints, such as the tyrosine phosphatase PTPN2 as a critical regulator of immunotherapy sensitivity in tumor cells. The Manguso lab has also developed new technologies for in vivo genetic screens and developed new screening methods for identifying factors that enhance the function of CAR T cells. The long-term goals of their research are to understand the basic mechanisms of immune evasion by tumors, develop therapeutic strategies to overcome immunotherapy resistance, and create new technologies and methods to probe the interactions between tumor cells and immune cells in vivo.